CV Outcomes Trials: FDA Actions, Announcements Paint Conflicted Picture
This article was originally published in The Pink Sheet Daily
Executive Summary
Policy of continuing safety trials into the post-approval setting gets favorable description in FDA meeting announcement, but delay of Contrave application suggests Orexigen may need to launch a new trial.